Paralytic Ileus

---

Overview

Definition

Paralytic ileus (adynamic ileus) is a temporary, functional form of intestinal obstruction caused by the disruption of normal peristaltic activity in the absence of a mechanical blockage. This disruption results from neuromuscular failure of the bowel wall, leading to luminal distension, impaired transit of intestinal contents, and accumulation of gas and fluid.

Epidemiology

Paralytic ileus is one of the most common causes of non-mechanical bowel obstruction, particularly in the inpatient setting. * Incidence: Varies widely, but occurs frequently after major abdominal surgery (postoperative ileus). Major abdominal operations carry an incidence of prolonged ileus (lasting >3-5 days) between 10% and 30%. * Demographics: Affects patients of all ages, though prevalence increases with age and complexity of surgical procedures.

Classification

While often grouped by etiology, the classification is primarily clinical: 1. Postoperative Ileus (POI): The most common form, typically resolving spontaneously within 2–3 days for the small bowel and 3–5 days for the colon (the return of bowel function is often sequential: small bowel $\rightarrow$ stomach $\rightarrow$ colon). 2. Non-Postoperative Ileus: Related to systemic illness, metabolic derangements, severe infection, or medications. 3. Colonic Pseudo-obstruction (Ogilvie Syndrome): A form of acute colonic dilatation mimicking mechanical obstruction, usually without underlying mechanical cause, often considered a highly localized form of paralytic ileus.

Pathophysiology

Mechanism

The underlying mechanism involves complex neural, inflammatory, and hormonal signaling that suppresses intestinal smooth muscle activity: 1. Reflex Inhibition (Neurogenic): * Surgical manipulation or peritoneal irritation stimulates inhibitory nerves (sympathetic splanchnic nerves), releasing inhibitory neurotransmitters (e.g., Norepinephrine), which suppress cholinergic activity and reduce peristalsis. * Spinal reflexes mediate this inhibition, particularly after retroperitoneal or spinal procedures. 2. Inflammatory Response: * Tissue trauma (surgery, ischemia) leads to the release of pro-inflammatory cytokines (e.g., IL-6, TNF-$\alpha$, IL-1$\beta$, inducible nitric oxide synthase [iNOS]). * iNOS-derived Nitric Oxide (NO) acts as a potent smooth muscle relaxant, sustaining the motility deficit. 3. Hormonal/Metabolic Derangement: * Hypokalemia, hypomagnesemia, and hyperglycemia can directly impair smooth muscle excitability and contractility.

Risk Factors

Category	Specific Risk Factors
Surgical	Extensive bowel handling, long operative time, open vs. laparoscopic approach (open often higher risk), opioid use (pre- and post-op), peritonitis/sepsis, anastomotic leak, retroperitoneal dissection.
Metabolic	Hypokalemia (<3.5 mEq/L), Hypomagnesemia, Hyperglycemia, Hyponatremia, Uremia, Ketoacidosis.
Medications	Opioids (major contributor), anticholinergics (e.g., tricyclic antidepressants), calcium channel blockers, phenothiazines.
Infections/Inflammation	Sepsis, Pneumonia (especially lower lobe), Peritonitis, Intra-abdominal abscess, Acute pancreatitis.
Neurological	Spinal cord injury, trauma, hemorrhage.

Protective Factors

• Minimally invasive surgery (laparoscopic approaches).
• Epidural anesthesia/analgesia (non-opioid dependent).
• Early enteral feeding and hydration.
• Opioid-sparing pain protocols (e.g., multimodal analgesia).
• Correction of electrolyte abnormalities pre- and post-operatively.

Clinical Presentation

Signs and Symptoms

Feature	Description
Cardinal Features	Abdominal distension, nausea, vomiting (often bilious or feculent in prolonged cases), inability to pass flatus or stool. Diffuse, non-localized abdominal pain (often described as pressure or cramping, though usually less severe than mechanical obstruction).
Early Signs	Reduced or absent bowel sounds, subjective feeling of bloating, minimal passage of flatus.
Advanced Signs	Significant tympanic abdominal distension, intractable vomiting, signs of dehydration (tachycardia, reduced skin turgor), electrolyte imbalance.
Atypical Presentations	May present solely as delayed tolerance of oral intake or isolated severe constipation, especially in elderly, frail patients.

Physical Examination

Examination Area	Findings Specific to Paralytic Ileus
Inspection	Generalized, non-localized abdominal distension. Absence of focal masses or hernia sites.
Auscultation	Crucial finding: Absent or markedly hypoactive "silent" bowel sounds (Borborygmi), often described as $<2$ sounds per minute or total silence for several minutes. (Contrast: Mechanical obstruction usually has high-pitched, hyperactive, "tinkling" sounds).
Palpation	Abdomen is usually soft and non-tender (in the absence of underlying peritonitis). Mild, diffuse tenderness to palpation may be present due to distension. No rebound tenderness or guarding.
Percussion	Tympany (drum-like sound) over the general abdomen due to trapped gas.
Special Tests	Rectal Examination: Absence of stool in the rectal vault, or presence of soft stool without significant impaction (unlike some mechanical obstructions).

Diagnostic Approach

History Taking

Key Questions	Clinical Significance
Recent Procedures?	Date and type of surgery (postoperative ileus timeline).
Last Flatus/Bowel Movement?	Defining the duration and severity of the motility deficit.
Medication Use?	Specifically asking about opiates, anticholinergics, or recent changes in dose.
Associated Symptoms?	Fever, localized pain (suggests abscess/peritonitis), urinary symptoms (suggests pyelonephritis/uremia).
Comorbidities?	Diabetes (risk of autonomic neuropathy), advanced renal disease, chronic pain.

Red Flags

• Localized, severe abdominal pain: Suggests mechanical obstruction, strangulation, perforation, or internal hernia.
• Fever >38.5°C or systemic signs of sepsis: Suggests ongoing infection (e.g., anastomotic leak, abscess, peritonitis).
• Peritoneal signs (rebound tenderness, guarding): Requires immediate investigation for perforation.
• Worsening tachycardia or hypotension: Signs of volume depletion or generalized sepsis.

Laboratory Tests

Test Category	Specific Tests and Rationale
First-Line	Complete Blood Count (CBC): Usually normal, leukocytosis may indicate underlying infection. Basic Metabolic Panel (BMP): Essential for identifying and quantifying electrolyte abnormalities ($\text{K}^+$, $\text{Mg}^{2+}$, $\text{Na}^+$). Renal Function Tests (BUN, Creatinine): Assess hydration and identify uremia.
Confirmatory	None, diagnosis is primarily clinical and radiological (exclusion of mechanical obstruction).
Monitoring	Daily or bid electrolyte checks during NPO status and IV fluid resuscitation. Serial lactates if concern for ischemia.

Imaging

Recommended (Standard Imaging Studies)

1. Abdominal Radiographs (Plain Films):
   • Findings: Diffuse, continuous gas and fluid levels in both the small and large bowel, often extending into the rectum (unlike mechanical obstruction, which classically shows gas cutoff at a transition point).
   • Air-Fluid Levels: Multiple, scattered air-fluid levels are common, but there is no classical stacking or "stepladder" pattern typically seen in SBO.
   • Goal: To rule out mechanical obstruction (e.g., volvulus, SBO) and perforation (free air under the diaphragm).
2. Computed Tomography (CT) Scan of the Abdomen/Pelvis (with IV and Oral Contrast):
   • Indication: When the clinical picture or plain films are unclear, or mechanical obstruction, ischemia, or abscess is suspected.
   • Findings: Dilated small and large bowel loops without a distinct transition zone. The caliber of the entire bowel tends to be uniformly dilated. Absence of features suggesting mechanical obstruction (e.g., closed loops, clustered loops, distinct transition point).
   • Differentiation: High accuracy in differentiating ileus from low-grade partial mechanical obstruction.

Advanced (Specialized Imaging when needed)

• Gastrografin swallow/Upper GI series: Rarely needed, but may help delineate a partial obstruction versus a long, severe ileus.

Management

The cornerstone of paralytic ileus management is supportive care and identification/correction of the underlying cause.

Acute Management

Intervention Focus	Specific Actions and Criteria
Immediate (First Hour)	NPO Status: Strict cessation of oral intake (NPO) to minimize distension. Nasogastric Tube (NGT): Placement for decompression if intractable vomiting, severe distension, or high output is present (often $>500 \text{ mL}/4 \text{ hr}$). Monitor NGT output.
Stabilization (Early)	IV Hydration: Aggressive intravenous crystalloid management (e.g., Normal Saline or Lactated Ringer's) to address third-spacing and volume deficit from vomiting and NG losses. Electrolyte Correction: Immediate and continuous correction of $\text{K}^+$ (target $\geq 4.0 \text{ mEq/L}$) and $\text{Mg}^{2+}$ (target $\geq 2.0 \text{ mg/dL}$).
Underlying Cause	Identify and treat the primary etiology: Stop or minimize culprit medications (opioid reduction, switching to non-opioid analgesics), manage sepsis, address pancreatitis, or treat pneumonia.

Chronic Management (Ongoing Supportive Care)

Pharmacological

No medications directly reverse paralytic ileus universally, but prokinetics may be useful based on etiology, especially in established/prolonged cases.

1. Opioid Antagonists (Peripheral):
   • Indication: Postoperative ileus (POI) associated with high opioid use.
   • Agents: Alvimopan (only approved for short-term hospital use, max 15 doses). Dosage: $12 \text{ mg}$ PO within 5 hours pre-surgery, then $12 \text{ mg}$ twice daily for up to 7 days post-surgery. Contraindicated in patients who have received therapeutic doses of opioids for more than seven consecutive days prior to surgery.
2. Prokinetics (Limited Role):
   • Erythromycin: Primarily acts on the stomach, but may stimulate motility (via motilin receptor agonism). Less effective for lower intestinal ileus.
   • Metoclopramide: Primarily upper GI prokinetic, generally ineffective for small or large bowel ileus.
3. Laxatives/Stool Softeners: Do not treat ileus itself but may be used cautiously once bowel function begins to return.

Non-pharmacological

• Ambulation: Early and frequent mobilization is critical to stimulating bowel motility.
• Gum Chewing: May stimulate cephalic-vagal reflexes, potentially reducing the duration of POI. Recommended use: 2-3 times daily for 30–60 minutes.
• Epidural Analgesia/Local Anesthetics: Continuous local anesthetic infiltration (e.g., paravertebral or TAP blocks) reduces systemic opioid requirements and may accelerate the return of gut function.

Treatment Algorithms

Level	Strategy	Specific Interventions
First-Line	Supportive Care & Etiology Correction	NPO/NGT Decompression, Aggressive IV Hydration, Electrolyte correction ($\text{K}, \text{Mg}$). Minimize opioids. Early ambulation.
Second-Line	Prokinetic/Peripheral Antagonists	Consider peripheral opioid antagonists (Alvimopan) in POI patients meeting criteria. Consider low-dose Neostigmine for Ogilvie syndrome (acute colonic pseudo-obstruction, but consult gastroenterology/surgery).
Refractory Cases	Advanced Decompression & Evaluation	Intermittent colonoscopic decompression (specifically for Ogilvie Syndrome with cecal diameter >12 cm or failure after 24-48 hours of medical management). Re-imaging (CT) to exclude missed mechanical obstruction or chronic inflammation.

---

Complications

Common

• Dehydration and Electrolyte Imbalances (Hypokalemia, metabolic alkalosis from vomiting/NGT).
• Aspiration Pneumonia (due to vomiting).
• Prolonged hospitalization and increased cost.

Serious (Specific to Ogilvie Syndrome)

• Cecal Perforation: The major life-threatening complication, occurring when massive colonic distention (cecal diameter typically exceeding $12-14 \text{ cm}$) compromises local circulation, leading to ischemia and perforation.

Long-term

• Recurrence of ileus if the underlying risk factors (e.g., chronic opioid use, chronic hypokalemia) are not addressed.
• Protracted nutritional deficits if NPO status is maintained for an extended period.

Prognosis

Factors Affecting Outcome

• Etiology: Ileus secondary to sepsis or diffuse peritonitis has a poorer prognosis than simple postoperative ileus.
• Comorbidities: Renal failure, heart failure, and malnutrition worsen outcomes.
• Cecal Diameter: In Ogilvie syndrome, diameter $>12 \text{ cm}$ significantly increases the risk of perforation and mortality.

Survival

• Simple postoperative ileus resolves spontaneously in the vast majority of cases (95-99%) and carries low direct mortality.
• Ileus related to severe systemic illness (e.g., septic shock) carries mortality linked to the underlying disease.

Quality of Life

Prolonged ileus dramatically decreases quality of life due to pain, nausea, restricted mobility, and extended hospital stay. Early resolution is key to functional recovery.

Prevention

Primary

• Anesthetic Technique: Use of thoracic epidural analgesia (local anesthetic combined with low-dose opioid) to reduce reliance on systemic opioids.
• Surgical Technique: Minimizing bowel manipulation, using minimally invasive surgery (laparoscopic).
• Opioid Sparing: Implementing ERAS (Enhanced Recovery After Surgery) protocols, focusing on multimodal pain management.
• Hydration/Electrolytes: Aggressive pre- and intraoperative correction of hypokalemia and hypomagnesemia.

Secondary

• Early Detection: Frequent monitoring of bowel sounds, flatus, and abdominal girth.
• Prompt NGT Insertion: Decompression at the first sign of severe, prolonged vomiting or distension.

Tertiary

• Nutritional Support: Initiation of total parenteral nutrition (TPN) if NPO status is anticipated to last more than 5–7 days, to prevent secondary malnutrition and poor wound healing.

Special Populations

Pediatric

• Etiology: Often secondary to viral gastroenteritis (rarely), severe systemic infection, or major congenital corrective surgery.
• Management: Fluid management must be meticulously monitored to prevent fluid overload or severe dehydration. NGT decompression is used cautiously.

Geriatric

• Considerations: Higher risk due to polypharmacy (more opioids, anticholinergics), frailty, and pre-existing comorbidities (e.g., autonomic neuropathy from long-standing diabetes).
• Pitfall: A silent abdomen may be normal in some elderly patients; rely more heavily on failure to pass flatus/stool and radiological evidence.

Pregnancy

• Diagnosis: Imaging (CT) should be avoided if possible. Ultrasound and careful X-rays are preferred.
• Management: Prokinetics (e.g., high-dose metoclopramide) should be used cautiously, though generally considered safe. Focus remains on supportive care and hydration.

Comorbidities

• Diabetes: Increased risk due to diabetic gastroparesis/autonomic neuropathy; requires tight glycemic control.
• Renal Failure: Electrolyte disturbances ($\text{K}^+, \text{Mg}^{2+}$) are more pronounced and difficult to manage, potentially requiring dialysis.

Clinical Pearls

Diagnostic

• The "Silent Abdomen" is key: The absence of bowel sounds (hypoactive to absent) is the classic sign distinguishing paralytic ileus from mechanical small bowel obstruction (hyperactive/metallic sounds).
• Rule out Ogilvie Syndrome: If the large bowel is significantly distended, measure the cecal diameter on imaging. If $>12 \text{ cm}$, treat aggressively for pseudo-obstruction.
• Always search for the etiology: If it's not a clear postoperative case, suspect infection (sepsis, abscess) or metabolic derangement first.

Treatment

• Minimize Opioids: This is arguably the single most important modifiable risk factor. Implement multimodal, non-opioid, or regional pain blocks.
• Don't Rush Prokinetics: Metoclopramide is often ineffective for small and large bowel ileus; use peripheral opioid antagonists (Alvimopan) specifically for POI if indicated.
• Keep the patient moving: Encourage early ambulation ($\geq 3$ times per day).

Pitfalls

• Assuming it's only ileus: Failure to perform serial clinical exams and re-imaging; a worsening ileus can mask a developing anastomotic leak, abscess, or low-grade mechanical obstruction.
• Premature Removal of NGT: Removing the tube too early (before resolving the underlying cause and documenting decreased output/return of GI function) can lead to rapid recurrence of vomiting and distension.

Recent Updates

Guidelines

• ERAS Society Guidelines: All current surgical guidelines (e.g., ERAS Society) strongly recommend multimodal pain control, epidural analgesia, early mobilization, and early enteral feeding to minimize the incidence and duration of postoperative ileus.
• Limited Role for Prokinetics: New guidelines generally reaffirm the limited evidence for central prokinetic agents (metoclopramide, erythromycin) in treating established paralytic ileus, unlike their use in gastroparesis.

Evidence

• Gum Chewing: Meta-analyses continue to support the use of gum chewing (sugar-free) in enhancing the time to first flatus and bowel movement reduction following colorectal surgery, likely via the stimulation of vagal pathways.
• Peripheral Opioid Antagonists: Studies confirm that agents like alvimopan safely reduce the duration of postoperative ileus by approximately 12–24 hours in appropriate candidates, facilitating earlier discharge.

Controversies

• Optimal Timing of Enteral Feeding: While early feeding is encouraged, the exact composition (low-residue vs. high-fiber) and timing in a patient with established, long-standing ileus remain debate points, though most support initiating liquids as tolerated once symptoms stabilize.

Key References

Guidelines

• ERAS Society Guidelines for Perioperative Care in Colorectal Surgery.
• American Society of Health-System Pharmacists (ASHP) Guidelines on Pain, Sedation, and Delirium (Relevance to opioid use).

Studies

• Multiple randomized controlled trials supporting the efficacy of peripheral opioid receptor antagonists (e.g., Alvimopan) for accelerated return of GI function.
• Systematic reviews and meta-analyses on the role of gum chewing in POI.

Reviews

• Reviews on the neuro-inflammatory pathophysiology of postoperative ileus, highlighting the role of iNOS and systemic inflammation.

---

Medical Disclaimer: This information is provided for clinical reference only and is not a substitute for professional medical judgment, diagnosis, or treatment. Clinicians must apply their professional expertise to make patient care decisions based on the individual patient's condition, current clinical guidelines, and available resources. Dosages and treatment recommendations are subject to change and should be confirmed with official product information or relevant regulatory bodies.